Catheter Precision Cracks German Market with Key Hospital Deal

FORT MILL, SC – January 22, 2026 – U.S. medical device company Catheter Precision, Inc. (NYSE/American: VTAK) announced today it has secured its first purchase order in Germany for its LockeT suture retention device, a move that establishes a critical foothold in Europe's largest and most influential healthcare market. The order from Universitätsklinikum Frankfurt (Frankfurt University Hospital), one of Germany’s premier medical institutions, marks the official commercial launch of LockeT in the country and signals a pivotal moment for the company's European expansion strategy.

This initial sale is more than just a transaction; it represents a strategic entry into the formidable German MedTech landscape. For a small-cap company like Catheter Precision, gaining access to a market renowned for its high standards and rigorous evaluation processes is a significant validation of its technology. The partnership with a leading university hospital provides a powerful reference site that could accelerate broader adoption across Germany and neighboring European nations.

“Securing our first purchase order from a prestigious German university hospital is a definitive turning point for Catheter Precision,” said David Jenkins, CEO of Catheter Precision, in a statement. “Germany represents the most significant healthcare market in Europe... This partnership validates the clinical value of our technology and serves as the cornerstone of our expansion strategy in the region.”

A Strategic Beachhead in Europe's MedTech Powerhouse

The importance of the German market cannot be overstated. With the German Electrophysiology Devices Market valued at over $900 million in 2024, it constitutes the largest segment in Europe, accounting for nearly 28% of the total revenue share. This market is part of a broader European electrophysiology sector projected to grow at a compound annual rate of over 10% to reach nearly $4.5 billion by 2030, fueled by an aging population and a rising prevalence of cardiac arrhythmias.

Penetrating this market through a partnership with Universitätsklinikum Frankfurt is a calculated and potent move. German university hospitals are the primary engines of medical innovation, serving as hubs for research, clinical trials, and the adoption of high-tech solutions. With over 1,300 beds and treating hundreds of thousands of patients annually, the Frankfurt hospital’s endorsement carries substantial weight. Its University Heart and Vascular Center is a leader in interdisciplinary care and research, making it an ideal environment to showcase the benefits of a new device like LockeT.

By establishing this institution as a reference site, Catheter Precision can demonstrate LockeT's real-world efficacy to other German and European hospitals, a classic and effective strategy for overcoming the inherent skepticism of a mature market. This first step provides the company with invaluable credibility as it seeks to scale its operations.

Innovating Wound Closure in Cardiac Procedures

At the heart of this expansion is the LockeT device itself, a Class 1 medical device with both FDA registration and European CE Mark approval. Designed to assist in wound closure following percutaneous venous punctures—common in cardiac electrophysiology procedures—LockeT is an external suture retention device. It is used in conjunction with a figure-of-eight stitch to secure the wound, promoting hemostasis (the stopping of bleeding).

The device's value proposition is centered on workflow efficiency and cost-effectiveness. In a busy catheterization lab, minutes matter. A device that simplifies and secures wound closure can save valuable time for clinicians. Catheter Precision asserts that LockeT provides efficient hemostasis, with data showing it achieved this milestone in 98% of patients within two hours. Furthermore, as an external device, it may offer safety advantages over internal vascular closure devices (VCDs) by potentially reducing the risk of thrombotic episodes.

The VCD market is competitive, dominated by industry giants like Abbott, Medtronic, and Cardinal Health, who offer a range of solutions from collagen plugs to clip-based systems. However, Catheter Precision is positioning LockeT as a user-friendly and potentially safer alternative. Its external application and compatibility with a standard suture technique could make it an attractive option for clinicians looking for a simple, reliable, and cost-effective method that avoids leaving a foreign body inside the vessel.

A High-Stakes Bet Amid Financial Headwinds

While the German market entry is a significant operational victory, it comes at a critical time for Catheter Precision. The company, which has a market capitalization of around $3.5 million, faces considerable financial challenges. Recent filings reveal deeply negative operating margins and a history of declining revenue, underscoring the high-stakes nature of its current growth strategy. The company executed a 1-for-19 reverse stock split in August 2025, a move often used to maintain compliance with stock exchange listing requirements.

Despite these pressures, the announcement was met with a positive, albeit moderate, market reaction, with VTAK's stock gaining over 4% in the trading session following the news. This German order is the latest in a series of international moves, including recent purchase orders and launches in Slovenia, Hungary, and Switzerland. This pattern suggests a concerted effort to build a revenue base across Europe, leveraging the CE Mark approval obtained in May 2025.

Investors are watching closely to see if this string of small victories can translate into a sustainable revenue stream that can reverse the company's financial trajectory. The success of the LockeT launch in Germany will be a key indicator of whether the company's technology and strategy can deliver on their promise and build long-term shareholder value.

The Realities of European Market Penetration

Achieving CE Mark approval is only the first step in a long journey for any U.S. medical device company entering Europe. The continent is not a single market but a patchwork of national healthcare systems, each with its own reimbursement policies, procurement processes, and clinical preferences. The European Union's stringent Medical Device Regulation (MDR) imposes rigorous requirements for clinical evidence and post-market surveillance, demanding a robust quality management system.

This is why Catheter Precision's strategy of establishing a strong reference site is so crucial. By proving LockeT's clinical utility and economic benefits within the demanding environment of Universitätsklinikum Frankfurt, the company can build a powerful case study. This evidence will be essential when approaching other hospitals and navigating the complex reimbursement negotiations in Germany and beyond. The success of this initial implementation will likely determine the pace and scale of the company's ability to capture a meaningful share of the lucrative European electrophysiology market.